Truist Securities Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $48
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Nicole Germino initiates coverage on Insmed (NASDAQ:INSM) with a Buy rating and a price target of $48.
April 23, 2024 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities initiated coverage on Insmed with a Buy rating and set a price target of $48.
The initiation of coverage by Truist Securities with a Buy rating and a significant price target suggests a positive outlook for Insmed's stock. This endorsement from a reputable analyst could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100